IDT at CSHL | 2024 Genome Engineering: CRISPR Frontiers

We can't wait to see you at the 2024 CSHL meeting, "Genome engineering: CRISPR frontiers!" Stop at our table to speak with our experts about how IDT's CRISPR genome editing solutions can help you rapidly move from the lab to therapeutic clinical applications.

Our CRISPR product portfolio includes a comprehensive set of tools, reagents, and services for all your genome editing needs, including discovery, preclinical research, and clinical applications. As your trusted partner, we're committed to providing you with the highest quality products and services to accelerate your research and bring your discoveries to life.

Special highlight: Workshop presentation

New products and services for efficient and safe CRISPR-based editing
(Registration to the "2024 CSHL genome engineering: CRISPR frontiers" meeting is required to attend the workshop. Register here.)

Thursday, August 29, 2024
Following the morning session

In this workshop, we will present data on an early development, an enzyme evolution project to identify an S.p. Cas9 variant that maintains editing efficiency and specificity with shortened sgRNAs. These gRNAs can be synthesized with greater fidelity of full-length product and provide a platform for prime editing gRNAs with greater purity.

Additionally, we have planned production of RUO and CGMP HDR enhancer proteins later this year and will present data on this evolved variant of an 53BP1 inhibitor that improves knock-in efficiency in tissue culture and primary cells while preventing an increase in translocation events that can occur from multiple double-stranded breaks in the genome. We will also present NGS-based solutions for assessing on- and off-target editing events and will share updates in oligonucleotide synthesis capabilities from RUO to CGMP.

Attend this event to explore:

• The development and benefits of an evolved S.p. Cas9 variant with shortened sgRNAs
• Improvements in knock-in efficiency with the new Alt-R™ HDR Enhancer Protein
• Advanced NGS solutions for assessing on- and off-target editing events
• CGMP guide RNA manufacturing services and regulatory support

IDT CRISPR Genome Editing Solutions

Research applications

Gene knock-out studies (non-homologous end joining, NHEJ)

Alt-R™ CRISPR-Cas9 System

Efficient CRISPR reagents based on the commonly used Streptococcus pyogenes Cas9 system for lipofection or electroporation experiments. Protospacer adjacent motif (PAM) = NGG.

Alt-R CRISPR-Cas12a (Cpf1) System

For additional target sites or for targeting AT-rich regions, use the CRISPR-Cas12a system in electroporation experiments. Protospacer adjacent motif (PAM) = TTTV. The Alt-R Cas12a (Cpf1) Ultra also can recognize many TTTT PAM sites in addition to TTTV motifs, increasing target range for genome editing studies.

Gene knock-in studies (homology-directed repair, HDR)

Alt-R HDR Design Tool* is a complete solution for high HDR rates based on wet bench testing and customer validation. It provides exceptional flexibility for seamless HDR design for your insertion, deletion, SNP, and amino acid mutation studies. Alt-R HDR Donor Oligos are enhanced Ultramer™ DNA oligos (up to 200 bases) specifically built for HDR. Alt-R HDR Donor Blocks are ideal for HDR-mediated insertions larger than 120 bases.

*Available for wild type/HiFi Cas9 or nickase designs.

Genome editing analysis

rhAmpSeq™ CRISPR Analysis System is an end-to-end solution to design, deploy, and analyze next generation sequencing data for on- and off-target interrogation after your CRISPR experiment.

Alt-R™ Genome Editing Detection Kit is a T7 endonuclease I (T7EI) mismatch cleavage assay for detection of on-target editing, known off-target events, and estimation of genome editing efficiency in cultured cells.

Therapeutic applications

CRISPR cGMP gRNA manufacturing
For customers looking to accelerate their CRISPR genome editing from discovery to clinical trials, our Engineering Run and full cGMP guide RNA manufacturing services offer a streamlined and regulatory-compliant solution. Backed by comprehensive documentation, our guide RNAs simplify regulatory filings, offering a straightforward path to clinical success. Get a free consultation with one of our clinical development leaders.

Aldevron CRISPR nucleases
For those applying gene editing to investigate and treat genetic and inherited diseases, these nucleases provide an accelerated path to the clinic by offering the same product manufactured at research grade and full cGMP, supported by the quality documentation necessary for regulatory filings.

Comprehensive Off-target Analysis Service
We have joined forces with SeQure Dx, experts in off-target analysis, to deliver unparalleled off-target editing analytical services for your CRISPR projects from research to clinic.